CA2769409A1 - Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes - Google Patents

Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes Download PDF

Info

Publication number
CA2769409A1
CA2769409A1 CA2769409A CA2769409A CA2769409A1 CA 2769409 A1 CA2769409 A1 CA 2769409A1 CA 2769409 A CA2769409 A CA 2769409A CA 2769409 A CA2769409 A CA 2769409A CA 2769409 A1 CA2769409 A1 CA 2769409A1
Authority
CA
Canada
Prior art keywords
nkg2d
antibody
diabetes
agent
mice
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2769409A
Other languages
English (en)
French (fr)
Inventor
Na XIONG
Mingcan Xia
David H. Raulet
Jacob Sten Petersen
Thora Brynja Boedvarsdottir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Penn State Research Foundation
University of California San Diego UCSD
Original Assignee
Penn State Research Foundation
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Research Foundation, University of California San Diego UCSD filed Critical Penn State Research Foundation
Publication of CA2769409A1 publication Critical patent/CA2769409A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
CA2769409A 2009-08-17 2010-08-16 Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes Abandoned CA2769409A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23442509P 2009-08-17 2009-08-17
US61/234,425 2009-08-17
US30411310P 2010-02-12 2010-02-12
US61/304,113 2010-02-12
PCT/US2010/045627 WO2011022334A1 (en) 2009-08-17 2010-08-16 Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes

Publications (1)

Publication Number Publication Date
CA2769409A1 true CA2769409A1 (en) 2011-02-24

Family

ID=43014101

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2769409A Abandoned CA2769409A1 (en) 2009-08-17 2010-08-16 Use of nkg2d inhibitors for treating cardiovascular and metabolic diseases, such as type 2 diabetes

Country Status (11)

Country Link
US (2) US20120148581A1 (https=)
EP (1) EP2467152B1 (https=)
JP (2) JP5838158B2 (https=)
KR (1) KR20120090931A (https=)
CN (1) CN102548573B (https=)
AU (1) AU2010284428B2 (https=)
BR (1) BR112012002353A2 (https=)
CA (1) CA2769409A1 (https=)
MX (1) MX2012001999A (https=)
RU (2) RU2015138677A (https=)
WO (1) WO2011022334A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2747785A4 (en) * 2011-08-26 2015-04-15 Univ California METHOD AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASES THROUGH NKG2D INHIBITION
EP2790696A1 (en) * 2011-12-16 2014-10-22 Atopix Therapeutics Limited Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
JP6200437B2 (ja) 2012-03-16 2017-09-20 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏ活性を調節するための方法および組成物
US20140235552A1 (en) * 2013-02-15 2014-08-21 Claresa Levetan Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent
JP2016523264A (ja) * 2013-07-03 2016-08-08 ユニバーシティ ヘルス ネットワーク Ｔｏｓｏに対する抗体
US20200157541A1 (en) * 2018-11-19 2020-05-21 Exosome Therapeutics, Inc. Exosome loaded therapeutics for the treatment of non-alcoholic steatohepatitis, diabetes mellitus type 1 and type 2, atherosclerotic cardiovascular disease, and alpha 1 antitrypsin deficiency
US12312584B2 (en) 2018-10-02 2025-05-27 Exosome Therapeutics, Inc. cGMP exosome loaded therapeutics for treating sickle cell disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004027902D1 (de) * 2003-03-24 2010-08-12 Scripps Research Inst Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
US7666417B2 (en) * 2003-04-22 2010-02-23 Fred Hutchinson Cancer Research Center Methods and compositions for treating autoimmune diseases or conditions
KR100912994B1 (ko) * 2004-04-05 2009-08-21 더 리전트 오브 더 유니버시티 오브 캘리포니아 Ｎｋｇ２ｄ의 조절
WO2008014035A2 (en) * 2006-07-25 2008-01-31 The Regents Of The University Of California Modulation of nkg2d and method for treating or preventing solid organ allograft rejection
KR101615935B1 (ko) * 2007-12-14 2016-04-28 노보 노르디스크 에이/에스 인간 ｎｋｇ2ｄ에 대한 항체 및 그것의 용도

Also Published As

Publication number Publication date
EP2467152A1 (en) 2012-06-27
AU2010284428B2 (en) 2014-09-11
JP5838158B2 (ja) 2015-12-24
RU2566264C2 (ru) 2015-10-20
AU2010284428A1 (en) 2012-02-16
EP2467152B1 (en) 2017-05-17
JP2016014030A (ja) 2016-01-28
KR20120090931A (ko) 2012-08-17
WO2011022334A1 (en) 2011-02-24
RU2012105528A (ru) 2013-09-27
RU2015138677A (ru) 2018-12-25
US20120148581A1 (en) 2012-06-14
CN102548573B (zh) 2016-03-16
US20150376281A1 (en) 2015-12-31
MX2012001999A (es) 2012-02-29
CN102548573A (zh) 2012-07-04
JP5978362B2 (ja) 2016-08-24
JP2013502420A (ja) 2013-01-24
BR112012002353A2 (pt) 2018-03-13

Similar Documents

Publication Publication Date Title
US20150376281A1 (en) Use of NKG2D Inhibitors for Treating Cardiovascular and Metabolic Diseases, Such as Type 2 Diabetes
KR102134088B1 (ko) Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
US8771696B2 (en) Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor
US20240002488A1 (en) Method of treating or preventing liver conditions
US11866513B2 (en) Anti-TMPRSS6 antibodies and uses thereof
EP2170950A1 (en) Anti-il-20 antibody and its use in treating il-20 associated inflammatory diseases
TW201348255A (zh) 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
US20220064277A1 (en) Use of anti-fam19a5 antibodies for treating atherosclerosis
JP2025525494A (ja) Ｃｎｘ抗原結合性分子
EP1517703B1 (en) Placental growth factor as a target for the treatment of osteoporosis
CA2805270C (en) Treatment of inflammatory disorders
AU2017200553B2 (en) Treatment of inflammatory disorders
CN121914278A (zh) 一种治疗非酒精性脂肪性肝病的双特异性抗体及其药物组合物
HK40126807A (zh) Cnx抗原结合分子
WO2018136913A1 (en) Inhibition of bone loss and inhibition of arthritis by cthrc1
UA112168C2 (uk) Антитіло, яке специфічно зв'язується з людським рецептором глюкагону
JP2012506406A (ja) 走化性因子阻害剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150720

FZDE Dead

Effective date: 20181129